Skip to main content

Analysts’ Top Healthcare Picks: Scholar Rock Holding (SRRK), Alcon (ALC)

Tipranks - Fri Mar 6, 12:22AM CST

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Scholar Rock Holding (SRRKResearch Report) and Alcon (ALCResearch Report) with bullish sentiments.

Claim 70% Off TipRanks Premium

Scholar Rock Holding (SRRK)

TD Cowen analyst Marc Frahm maintained a Buy rating on Scholar Rock Holding yesterday. The company’s shares closed last Wednesday at $47.43.

According to TipRanks.com, Frahm is a 5-star analyst with an average return of 18.7% and a 50.5% success rate. Frahm covers the Healthcare sector, focusing on stocks such as Monte Rosa Therapeutics, Janux Therapeutics Inc, and Revolution Medicines. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Scholar Rock Holding with a $56.60 average price target, representing a 23.6% upside. In a report issued on March 3, H.C. Wainwright also maintained a Buy rating on the stock with a $58.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Alcon (ALC)

In a report released yesterday, Richard Felton from Goldman Sachs maintained a Buy rating on Alcon, with a price target of $105.00. The company’s shares closed last Wednesday at $84.27.

Felton has an average return of 3.0% when recommending Alcon. ;'>

According to TipRanks.com, Felton is ranked #3688 out of 12134 analysts.

Currently, the analyst consensus on Alcon is a Moderate Buy with an average price target of $95.48, a 13.8% upside from current levels. In a report issued on February 26, Wells Fargo also upgraded the stock to Buy with a $97.00 price target.

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.